Surmodics | SRDX - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Abbott USD 9.21B 17M 2025-12
Align Technology USD 822.85M 11.8M 2025-12
Anika Therapeutics USD 29.97M 116.84M 2025-12
Arrowhead Research USD 223.22M 10.86M 2025-12
Artivion USD 111.2M 9.45M 2025-12
Baxter International USD 3.19B 554.4M 2025-12
Boston Scientific USD 4.04B 18M 2025-12
EDAP TMS EUR 18.8M 3.01M 2025-09
Edwards Lifesciences USD 1.2B 71.3M 2025-12
Haemonetics USD 134.99M 1.26M 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
J&J USD 17.44B 1.53B 2026-03
Merit Medical Systems USD 339.74M 1.8M 2025-12
Mesa Laboratories USD 33.98M 2.03M 2024-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Option Care Health USD 1.37B 23.44M 2025-12
Stryker USD 5.2B 505M 2025-12
Surmodics USD 29.51M 274.86M 2025-06
Trinity Biotech USD 14.82M 7.81M 2025-09